Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Regeneron acquires 23andMe for $256 million following its bankruptcy. The deal includes DNA data access, raising privacy ...

The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business ...

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime editing-based pipeline focus to liver disease and programs funded by external ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.